News & Updates

Show Multimedia Only
Donanemab delays Alzheimer's disease progression over 3 years

Donanemab delays Alzheimer's disease progression over 3 years

04 Jun 2026 byKanas Chan

Donanemab administered for a limited duration continues to slow clinical progression in patients with early symptomatic Alzheimer’s disease (AD) over 3 years, according to Professor Chaur-Jong Hu of the Department of Neurology, Taipei Medical University, who spoke at Advances in Medicine (AIM) 2026. 

04 Jun 2026
Blood test detects signs of Alzheimer’s disease in midlife

Blood test detects signs of Alzheimer’s disease in midlife

02 Jun 2026 byKanas Chan

Blood test can identify signs of accumulation of highly accurate Alzheimer’s Disease (AD)–associated biomarkers in the brains of middle-aged adults, a large community-based cohort study has shown. 

02 Jun 2026